Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.63 |
| ▸ | CHUK | O15111 | 4/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
| ▸ | PAK4 | O96013 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | IGF1R | P08069 | 1/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
| ▸ | LTK | P29376 | 1/20 | 0.63 |
| ▸ | GRK5 | P34947 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857421 | 0.86 | NUDT1 (0.69) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL12127926 | 0.85 | IKBKB (0.70) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL857132 | 0.80 | IKBKB (0.63) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL2240671 | 0.80 | AURKB (0.71) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL10125136 | 0.78 | NUDT1 (0.68) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL2240257 | 0.77 | IKBKB (0.74) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL857275 | 0.77 | IKBKB (1.00) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL18440646 | 0.76 | IKBKB (0.48) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL12127494 | 0.76 | BRD4 (0.70) | IKBKBCHUKAURKBDAPK3JAK2 | |
| SCHEMBL2240782 | 0.75 | AURKB (0.61) | IKBKBCHUKAURKBDAPK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-1696920-B1 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | IKBKB 387/4885CHUK 210/4885AURKB 121/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | IKBKB 387/4885CHUK 210/4885AURKB 121/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | IKBKB 387/4885CHUK 210/4885AURKB 121/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | IKBKB 1808/4885CHUK 173/4885AURKB 625/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | IKBKB 387/4885CHUK 210/4885AURKB 121/4885 |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | IKBKB 138/4885CHUK 31/4885AURKB 394/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | IKBKB 2317/4885CHUK 426/4885AURKB 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.